Biopharmaceutical News and Research

RSS

Stapled Peptides directly inhibit the Notch transcription factor complex

Aileron Therapeutics, a biopharmaceutical company leading the development of a new class of drugs called Stapled Peptides, announced today that its collaborators, James E. Bradner, MD of the Dana-Farber Cancer Institute and the Broad Institute of Harvard and MIT, and Gregory L. Verdine, PhD, Professor of Chemistry at Harvard University, published research in Nature entitled, “Direct Inhibition of the Notch Transcription Factor Complex.”

12 Nov 2009

PIKAMAB announces the development of ADCC Therasight, a novel theragnostic product

PIKAMAB, a stratified medicine biopharmaceutical company, announced today that it is developing ADCC TherasightTM, a novel theragnostic product that can help guide the drug development process and patient treatment protocols for the cancer therapeutic antibodies that use ADCC (antibody-dependent cellular cytotoxicity) as the major mechanism of action.

12 Nov 2009

Stapled Peptides can inhibit key intracellular biological targets, says new research

Aileron Therapeutics, a biopharmaceutical company leading the development of a new class of drugs called Stapled Peptides, announced today that its collaborators, James E. Bradner, MD of the Dana-Farber Cancer Institute and the Broad Institute of Harvard and MIT, and Gregory L. Verdine, PhD, Professor of Chemistry at Harvard University, published research in Nature entitled, "Direct Inhibition of the Notch Transcription Factor Complex." Results presented in the paper showed that Stapled Peptides can potently and directly inhibit the transcription factor Notch, an oncogene implicated in cancer cell proliferation and survival.

12 Nov 2009

Data from Phase IIa clinical trial evaluating VT-111 to be presented by Viron Therapeutics at AHA conference

Viron Therapeutics Inc., a biopharmaceutical company pioneering the development of viral protein therapeutics, announced today that the Company's research collaborator, Dr. Jean-Claude Tardif, Director of the Research Center at the Montreal Heart Institute, will present data from a Phase IIa clinical trial evaluating VT-111 at the American Heart Association (AHA) Scientific Sessions 2009 conference. The conference will take place in Orlando, Florida from November 14 to 18, 2009.

12 Nov 2009

New biopharmaceutical business intelligence tool from Deloitte Recap

Deloitte Recap LLC (Recap) has launched "Development Optimizer," the third product in the Recap IQ Series by Deloitte. The series of biopharmaceutical business intelligence tools are part of a new subscription service tailored toward business development, corporate strategy, financial, clinical development, legal, academic and R&D professionals.

11 Nov 2009

Online patient support program for ADHD patients taking Vyvanse Capsules CII medication

Shire plc (LSE: SHP, Nasdaq: SHPGY), the global specialty biopharmaceutical company, today announced the re-launch of FOCUS (http://www.vyvanseFOCUS.com), a free, online patient support program for adults taking once-daily Vyvanse® (lisdexamfetamine dimesylate) Capsules CII for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD), and the only online, branded personalized patient support program providing tips and tools for adults diagnosed with ADHD taking a prescription medication.

11 Nov 2009

Aeterna Zentaris reports consolidated revenues of $8.6 million for third quarter 2009

AEterna Zentaris Inc., a global biopharmaceutical company focused on endocrinology and oncology, today reported financial and operating results as at and for the three-month and nine-month periods ended September 30, 2009.

11 Nov 2009

Biopharma leaders to discuss optimized clinical operations and outsourcing strategies at iiBIG's forum

iiBIG and the newly formed Global Biopharmaceutical Advisory Board have jointly planned an event that will focus on one of the most dynamic trends in the pharmaceutical, biotechnology, and medical device industries -- strategic outsourcing. Biopharma CEOs, VPs of Global Operations, and Department Heads will meet at the 4th Annual Global Clinical Trial Partnerships, March 1-2, 2010, in Princeton, New Jersey to discuss the latest strategies for optimizing global operations.

11 Nov 2009

WebMD Health inks agreement with Drugs.com

WebMD Health Corp., the leading source of health information, announced today that it has entered into an alliance with Drugs.com to exclusively integrate Drugs.com's advertising inventory and online traffic into the WebMD Health Network. Drugs.com provides free, accurate and independent information on more than 24,000 prescription drugs, over-the-counter medicines and natural products.

11 Nov 2009

Epilepsy Therapy Project invests $100,000 in NeuroTherapeutics Pharma

NeuroTherapeutics Pharma, Inc., or NTP, a biopharmaceutical company focused on developing novel therapies for central nervous system (CNS) disorders, today announced that it received a $100,000 investment from the Epilepsy Therapy Project.

11 Nov 2009

Tokai Pharmaceuticals commences TOK-001 Phase 1/2 clinical trial for treatment of castration resistant prostate cancer

Tokai Pharmaceuticals, Inc., a biopharmaceutical company focused on developing new treatments for prostate cancer, today announced the initiation of a Phase 1/2 clinical trial of its lead candidate TOK-001 for the treatment of patients with castration resistant prostate cancer (CRPC). TOK-001 is the only compound in development that combines three distinct mechanisms of action for the treatment of CRPC.

10 Nov 2009

ImmunoGen to present IMGN901 clinical data at AACR-NCI-EORTC International Conference

ImmunoGen, Inc., a biopharmaceutical company that develops targeted anticancer therapeutics, announced today that several ImmunoGen poster presentations will be made at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics to be held in Boston, MA, on November 15-19, 2009.

10 Nov 2009

Tailwind Capital announces the completion of investment in SDI Health

Tailwind Capital, a private equity firm focused on growing companies in the healthcare, business services, and media/communications sectors of the middle market, announced today that it has completed an investment in SDI Health (“SDI”). SDI is a leading healthcare analytics provider based in Plymouth Meeting, PA. Tailwind joins founder Andrew Kress and Philadelphia-based LLR Partners as investors in the Company.

10 Nov 2009

Scientific article supports AEterna Zentaris' development of perifosine inhibitor

AEterna Zentaris Inc., a global biopharmaceutical company focused on endocrine therapy and oncology, today announced publication of a scientific article in the renowned Journal of Urology, supporting the development of the Company's PI3K/Akt pathway inhibitor oral compound, perifosine, for the treatment of cancer.

9 Nov 2009

Shire's INTUNIV for treating ADHD now available in the U.S.

Shire plc, the global specialty biopharmaceutical company, today announced the availability of INTUNIV(TM) (guanfacine) Extended Release Tablets in pharmacies across the United States for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in children and adolescents ages 6 to 17.

9 Nov 2009

Clinipace acquires Worldwide Clinical Research, changes its name to Clinipace Worldwide

Clinipace, a global technology-driven clinical research organization (CRO), announced today that on October 26th, 2009 the company closed its acquisition of Worldwide Clinical Research, Inc. (WWCR), a Midwest-based CRO specializing in the management of clinical studies for biotechnology and pharmaceutical companies. With the acquisition, Clinipace has changed its name to Clinipace Worldwide.

9 Nov 2009

CytRx reports financial results for the three months and nine months ended September 30, 2009

CytRx Corporation, a biopharmaceutical company, today reported financial results for the three months and nine months ended September 30, 2009.

9 Nov 2009

PAREXEL International forms an alliance with Mortara Instrument, enhances cardiac safety capabilities

PAREXEL International Corporation, a leading global biopharmaceutical services provider, today announced that it has enhanced its cardiac safety capabilities for early phase clinical development through an alliance with Mortara Instrument, Inc., which manufactures and distributes electrocardiogram (ECG) devices and related technology worldwide.

From Parexel 9 Nov 2009

HUYA Bioscience International and School of Medicine and Pharmacy enter into partnership agreement

HUYA Bioscience International, a leader in globalizing China's biopharmaceutical innovation, today announced a strategic partnership with the School of Medicine and Pharmacy, Ocean University of China.

9 Nov 2009

Biopharma companies need to incorporate innovative elements in their business models to survive healthcare reform

Those biopharmaceutical companies that are able to incorporate innovative and flexible elements into their business models will be best positioned to survive healthcare reform and maintain attractive long-term returns, according to a white paper published today by Cowen Healthcare Royalty Partners, a global healthcare private equity firm, and Health Advances, a leading healthcare strategy firm.

7 Nov 2009

Biopharmaceutical News and Research

Stapled Peptides directly inhibit the Notch transcription factor complex

PIKAMAB announces the development of ADCC Therasight, a novel theragnostic product

Stapled Peptides can inhibit key intracellular biological targets, says new research

Data from Phase IIa clinical trial evaluating VT-111 to be presented by Viron Therapeutics at AHA conference

New biopharmaceutical business intelligence tool from Deloitte Recap

Online patient support program for ADHD patients taking Vyvanse Capsules CII medication

Aeterna Zentaris reports consolidated revenues of $8.6 million for third quarter 2009

Biopharma leaders to discuss optimized clinical operations and outsourcing strategies at iiBIG's forum

WebMD Health inks agreement with Drugs.com

Epilepsy Therapy Project invests $100,000 in NeuroTherapeutics Pharma

Tokai Pharmaceuticals commences TOK-001 Phase 1/2 clinical trial for treatment of castration resistant prostate cancer

ImmunoGen to present IMGN901 clinical data at AACR-NCI-EORTC International Conference

Tailwind Capital announces the completion of investment in SDI Health

Scientific article supports AEterna Zentaris' development of perifosine inhibitor

Shire's INTUNIV for treating ADHD now available in the U.S.

Clinipace acquires Worldwide Clinical Research, changes its name to Clinipace Worldwide

CytRx reports financial results for the three months and nine months ended September 30, 2009

PAREXEL International forms an alliance with Mortara Instrument, enhances cardiac safety capabilities

HUYA Bioscience International and School of Medicine and Pharmacy enter into partnership agreement

Biopharma companies need to incorporate innovative elements in their business models to survive healthcare reform

Oxygen Measurement eBook - Easily Understand Dissolved Oxygen Measurement eBook

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News